For decades, the US FDA has drawn a bright line when describing the limits of its regulatory authority: the agency can decide whether new medicines are permitted to be marketed and can limit the scope of claims about their intended use, but the agency does not regulate the practice of medicine.
That line has gotten more and more blurry in the context of FDA’s response to the opioid abuse crisis, where...







